Barbexaclon

Structural formula
General
Non-proprietary name	Barbexaclon
other names	(-) - N , α-Dimethylcyclohexaneethylammonium-5-ethyl-5-phenyl-barbiturate ( IUPAC )
Molecular formula	C 12 H 12 N 2 O 3 • C 10 H 21 N
External identifiers / databases
CAS number 4388-82-3 EC number 224-504-7 ECHA InfoCard 100.022.278 PubChem 71196 ChemSpider 64332 DrugBank DB09001 Wikidata Q409549
Drug information
ATC code	N03 AA04
Drug class	sedative Anticonvulsant Anti-epileptic
properties
Molar mass	387.52 g mol −1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed GHS hazard labeling no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Barbexaclon is a drug from the group of barbiturates used to treat various forms of epilepsy . Chemically speaking, it is a salt-like compound made up of phenobarbital and propylhexedrine . The individual components become effective after absorption . An additive or synergistic effect of the stimulant propylhexedrine to the antiepileptic effect of the phenobarbital could not be proven in animal experiments. Barbexaclon is now obsolete and only approved as a medicinal product in a few countries. In Italy, Switzerland and Austria it was marketed by the pharmaceutical company Abbott until 2009 under the trade name Maliasin .

Narcotics regulations

Internationally, Barbexaclon falls under the Convention on Psychotropic Substances . In Germany it is classified as a marketable narcotic drug and is subject to a separate prescription, provided the drug contains no less than 300 mg of substance (calculated as phenobarbital) per tablet or ampoule . Handling without permission or prescription is generally punishable.

Individual evidence

1. ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
2. ^ ^{A b} M. Albinus: Hager's handbook of pharmaceutical practice: substances E – O. Birkhäuser, 1993. p. 372.
3. ↑ P. Berlit: Therapielexikon Neurologie. Springer, 2004. p. 162.
4. ↑ SPC for Maliasin ABBOTT in drug compendium of Switzerland - as of January of 2004.
5. ↑ ABDA database (as of December 4, 2009).
6. ↑ Appendix III of the Narcotics Act .

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !